SCHEMBL16632584

SCHEMBL16632584

COc1cc(Cl)ccc1Oc1cccc2ccoc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.48
SLC6A2 P23975 6/20 0.48
SLC6A3 Q01959 4/20 0.48
KCNH2 Q12809 1/20 0.48
TSHR P16473 3/20 0.43
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 3/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TTR P02766 2/20 0.42
DHPS P49366 1/20 0.40
ACHE P22303 2/20 0.39
BCHE P06276 1/20 0.38
RAB9A P51151 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632498 0.82 TTR (0.51) SLC6A2SLC6A3TSHRNPC1MAPT
SCHEMBL595172 0.78 ALDH1A1 (0.58) NPC1SMN1; SMN2MAPTKMT2AHPGD
SCHEMBL16632750 0.78 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3KCNH2MAPT
SCHEMBL29876410 0.77 CYP3A4 (0.51) SLC6A4SLC6A2SLC6A3KCNH2MAPT
SCHEMBL676629 0.70 TTR (0.73) SLC6A4SLC6A2SLC6A3KCNH2MAPT
SCHEMBL3154096 0.70 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3KCNH2SMN1; SMN2
SCHEMBL16632535 0.69 SLC6A2 (0.47) SLC6A4SLC6A2SLC6A3KCNH2KMT2A
SCHEMBL2127233 0.69 TRPV4 (0.55) SLC6A4SLC6A2SLC6A3KCNH2TSHR
SCHEMBL29636402 0.69 TRPV4 (0.55) SLC6A4SLC6A2SLC6A3KCNH2TSHR
SCHEMBL10158521 0.69 CYP3A4 (0.42) SLC6A3TSHRSMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR SLC6A4 4266/4885SLC6A2 3227/4885SLC6A3 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.